Ranbaxy Laboratories completes 20 years in Ukraine

20 Nov 2013 Evaluate

Ranbaxy Laboratories, India’s largest pharmaceutical company, is celebrating its 20th anniversary in Ukraine. Establishing its operation in the Ukraine market in 1993, Ranbaxy is today the number 1 player in the target market segment with key brands such as Cifran (Ciprofloxacin), Zanocin (Ofloxacin) and Ketanov (Ketorolac) and a market share of 10.3% (Morion, MAT Q3, 2013).

Over the past two decades, the company has established a robust distribution network in Ukraine and is today catering to 25 regions. The company markets branded generic and over-the-counter (OTC) products and is well known for its innovative marketing capabilities with a number of brands in leadership position.

Besides, the therapeutic segments cover anti-infectives, gastrointestinal, cardiovascular, non-steroidal anti-inflammatory drugs (NSAID), urology, OTC and Anti-retrovirals (ARVs). Some of the leading brands in Ukraine include Ketanov, Pylobact NEO, Candesar range, Cifran, Synerpen and Faringosept. The company has in the past, bagged the prestigious Panacea Award for Ketanov, Cifran and Faringosept.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×